Skip to main content

Advertisement

SpringerLink
Log in

TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what’s new?

  • Review Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

TNF-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein of the TNF superfamily that serves as an extracellular signal that triggers programmed cell death in tumor cells, without affecting normal cells. Recently, scientists have turned their attention to the emerging role of TRAIL in immune and autoimmune responses. TRAIL has been shown to down-regulate the self-antigens in autoimmune diseases, such as rheumatoid arthritis (RA) by exerting its apoptotic effect on activated T cells and synoviocytes and by its local anti-inflammatory effect. The impact of TRAIL molecular variants and agonistic monoclonal antibodies in the regulation of TRAIL activity in arthritis animal models strongly supports the idea of testing the role of TRAIL in humans, with the aim of developing new effective therapies that promote apoptosis of synoviocytes and/or infiltrating lymphocytes, by targeting TRAIL. The aim of this review is to summarize recent progress and current knowledge of TRAIL functions in RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673–682

    Article  CAS  PubMed  Google Scholar 

  2. Mariani SM, Krammer PH (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 28:973–982

    Article  CAS  PubMed  Google Scholar 

  3. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J (1997) Characterization of two receptors for TRAIL. FEBS Lett 416:329–334

    Article  CAS  PubMed  Google Scholar 

  4. Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386–5397

    Article  PubMed Central  PubMed  Google Scholar 

  5. Suliman A, Lam A, Datta R, Srivastava RK (2001) Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20:2122–2133

    Article  CAS  PubMed  Google Scholar 

  6. Neumann S, Bidon T, Branschädel M, Krippner-Heidenreich A, Scheurich P, Doszczak M (2012) The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity. PLoS ONE 7:e42526

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165–1170

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 7:1003–1006

    Article  CAS  PubMed  Google Scholar 

  9. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363–14367

    Article  CAS  PubMed  Google Scholar 

  10. Allen JE, El-Deiry WS. (2012) Regulation of the human TRAIL gene. Cancer Biol Ther 13(12):1143–1151

    Google Scholar 

  11. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356–1361

    Article  CAS  PubMed  Google Scholar 

  12. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155–162

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157–163

    Article  CAS  PubMed  Google Scholar 

  14. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833–2840

    CAS  PubMed  Google Scholar 

  15. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99:618–624

    Article  CAS  PubMed  Google Scholar 

  16. Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M (1998) APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 427:124–128

    Article  CAS  PubMed  Google Scholar 

  17. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P (1999) Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59:2747–2753

    CAS  PubMed  Google Scholar 

  18. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS (2007) Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 13(15 Pt 1):4556–4564

    Article  CAS  PubMed  Google Scholar 

  19. Caron G, Delneste Y, Aubry JP, Magistrelli G, Herbault N, Blaecke A, Meager A, Bonnefoy JY, Jeannin P (1999) Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur J Immunol 29:3588–3595

    Article  CAS  PubMed  Google Scholar 

  20. Halaas O, Vik R, Ashkenazi A, Espevik T (2000) Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 51:244–250

    Article  CAS  PubMed  Google Scholar 

  21. Kaplan MJ, Ray D, Mo RR, Yung RL, Richardson BC (2000) TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4 + T cell killing of antigen-presenting macrophages. J Immunol 164:2897–2904

    Article  CAS  PubMed  Google Scholar 

  22. Liu S, Yu Y, Zhang M, Wang W, Cao X (2001) The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 166:5407–5415

    Article  CAS  PubMed  Google Scholar 

  23. Song K, Chen Y, Göke R, Wilmen A, Seidel C, Göke A, Hilliard B, Chen Y (2000) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191:1095–1104

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Jin CH, Chae SY, Kim TH, Yang HK, Lee EY, Song YW, Jo DG, Lee KC (2010) Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J Pharmacol Exp Ther 332:858–865

    Article  CAS  PubMed  Google Scholar 

  25. Yao Q, Wang S, Gambotto A, Glorioso JC, Evans CH, Robbins PD, Ghivizzani SC, Oligino TJ (2003) Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 10:1055–1060

    Article  CAS  PubMed  Google Scholar 

  26. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, Wang Z, Liu D, Mountz JD, Ohtsuki M, Koopman WJ, Kimberly R, Zhou T (2003) TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J. Immunol 171:1061–1069

    Article  CAS  PubMed  Google Scholar 

  27. Miyashita T, Kawakami A, Tamai M, Izumi Y, Mingguo H, Tanaka F, Abiru S, Nakashima K, Iwanaga N, Aratake K, Kamachi M, Arima K, Ida H, Migita K, Origuchi T, Tagashira S, Nishikaku F, Eguchi K (2003) Akt is an endogenous inhibitor toward tumor necrosis factor-related apoptosis inducing ligand-mediated apoptosis in rheumatoid synovial cells. Biochem Biophys Res Commun 312:397–404

    Article  CAS  PubMed  Google Scholar 

  28. Morel J, Audo R, Hahne M, Combe B (2005) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 280:15709–15718

    Article  CAS  PubMed  Google Scholar 

  29. Perlman H, Nguyen N, Liu H, Eslick J, Esser S, Walsh K, Moore TL, Pope RM (2003) Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3. Arthritis Rheum 48:3096–3101

    Article  PubMed  Google Scholar 

  30. Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, Weedon H, Chen P, Screaton G, Xu XN, Haynes DR (2009) Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther 11:R13

    Article  PubMed Central  PubMed  Google Scholar 

  31. Audo R, Combe B, Coulet B, Morel J, Hahne M (2009) The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases. Cell Death Differ 16:1227–1237

    Article  CAS  PubMed  Google Scholar 

  32. Tamai M, Kawakami A, Tanaka F, Miyashita T, Nakamura H, Iwanaga N, Izumi Y, Arima K, Aratake K, Huang M, Kamachi M, Ida H, Origuchi T, Eguchi K (2006) Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma through JAK/STAT pathway by translational regulation. J Lab Clin Med 147:182–190

    Article  CAS  PubMed  Google Scholar 

  33. Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Tanaka F, Kamachi M, Ida H, Migita K, Origuchi T, Nakao K, Eguchi K (2004) Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 137:430–436

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Audo R, Calmon-Hamaty F, Baeten D, Bruyer A, Combe B, Hahne M, Morel J (2011) Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 63:904–913

    Article  CAS  PubMed  Google Scholar 

  35. Pundt N, Peters MA, Wunrau C, Strietholt S, Fehrmann C, Neugebauer K, Seyfert C, van Valen F, Pap T, Meinecke I (2009) Susceptibility of rheumatoid arthritis synovial fibroblasts to FasL- and TRAIL-induced apoptosis is cell cycle-dependent. Arthritis Res Ther 11(1):R16

    Article  PubMed Central  PubMed  Google Scholar 

  36. Xie YD, Jin L, Yu QW (2007) The role of IFN-gamma, IL-10, IL-12 and TRAIL in sera and synovium fluids from patients with rheumatoid arthritis]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23:536–537

    CAS  PubMed  Google Scholar 

  37. Miranda-Carús ME, Balsa A, Benito-Miguel M, De Ayala CP, Martín-Mola E (2004) Rheumatoid arthritis synovial fluid fibroblasts express TRAIL-R2 (DR5) that is functionally active. Arthritis Rheum 50:2786–2793

    Article  PubMed  Google Scholar 

  38. Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S (2010) TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8 + T cells correlate with the disease severity in patients with rheumatoid arthritis. BMC Musculoskelet Disord 11:192

    Article  PubMed Central  PubMed  Google Scholar 

  39. Xiao H, Wang S, Miao R, Kan W (2011) TRAIL is associated with impaired regulation of CD4 + CD25- T cells by regulatory T cells in patients with rheumatoid arthritis. J Clin Immunol 31:1112–1119

    Article  CAS  PubMed  Google Scholar 

  40. Secchiero P, Corallini F, Castellino G, Bortoluzzi A, Caruso L, Bugatti S, Bosco R, Montecucco M, Trotta F (2010) Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs. J Rheumatol 37:1461–1466

    Article  CAS  PubMed  Google Scholar 

  41. Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P. (2012) Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 79:591–596

    Google Scholar 

  42. Schneemann M, Schoeden G (2007) Macrophage biology and immunology: man is not a mouse. J Leukoc Biol 81:579–580

    Article  CAS  PubMed  Google Scholar 

  43. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, Lang R, Haniffa M, Collin M, Tacke F et al (2010) Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115:10–19

    Article  Google Scholar 

  44. Misharin AV, Haines GK 3rd, Rose S, Gierut AK, Hotchkiss RS, Perlman H (2012) Development of a new humanized mouse model to study acute inflammatory arthritis. J Transl Med 10:190

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Yao Q, Seol DW, Mi Z, Robbins PD (2006) Intra-articular injection of recombinant TRAIL induces synovial apoptosis and reduces inflammation in a rabbit knee model of arthritis. Arthritis Res Ther 8:R16

    Article  PubMed Central  PubMed  Google Scholar 

  46. Terzioglu E, Bisgin A, Sanlioglu AD, Ulker M, Yazisiz V, Tuzuner S, Sanlioglu S (2007) Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis. Rheumatology (Oxford) 46:783–789

    Article  CAS  Google Scholar 

  47. Liu Z, Xu X, Hsu HC, Tousson A, Yang PA, Wu Q, Liu C, Yu S, Zhang HG, Mountz JD (2003) CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 112:1332–1341

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Na SJ, Chae SY, Lee S, Park K, Kim K, Park JH, Kwon IC, Jeong SY, Lee KC (2008) Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand. Int J Pharm 363:149–154

    Article  CAS  PubMed  Google Scholar 

  49. Kim YJ, Chae SY, Jin CH, Sivasubramanian M, Son S, Choi KY, Jo DG, Kim K, Chan Kwon I, Lee KC, Park JH (2010) Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis. Biomaterials 31:9057–9064

    Article  CAS  PubMed  Google Scholar 

  50. Martinez-Lostao L, García-Alvarez F, Basáñez G, Alegre-Aguarón E, Desportes P, Larrad L, Naval J, Martínez-Lorenzo MJ, Anel A (2010) Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 62:2272–2282

    Article  CAS  PubMed  Google Scholar 

  51. Andersson IE, Batsalova T, Dzhambazov B, Edvinsson L, Holmdahl R, Kihlberg J, Linusson A (2010) Oxazole-modified glycopeptides that target arthritis-associated class II MHC A(q) and DR4 proteins. Org Biomol Chem 8:2931–2940

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, Rheumatology Clinic, University of Foggia, Ospedale “Col. D’Avanzo”, V.le degli Aviatori 1, 71100, Foggia, Italy

    Anna Neve, Addolorata Corrado & Francesco Paolo Cantatore

Authors
  1. Anna Neve
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Addolorata Corrado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Paolo Cantatore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Paolo Cantatore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neve, A., Corrado, A. & Cantatore, F.P. TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what’s new?. Clin Exp Med 14, 115–120 (2014). https://doi.org/10.1007/s10238-012-0226-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-012-0226-1

Keywords

Search

Navigation